Following encouraging interim data from the Phase II REDUC trial of Vacc- 4x with romidepsin, Bionor has set a number of initiatives in motion to fully capitalise on the potential opportunity that this ‘Kick and Kill’ approach could offer in HIV. This includes planning next development steps by convening an expert panel, securing future romidepsin supply and exploring potential financing options. These endeavours should ensure that Bionor will be well-placed to swiftly advance Vac
13 Aug 2015
Prepping for the future; REDUC read-out in H215
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prepping for the future; REDUC read-out in H215
- Published:
13 Aug 2015 - Author:
- Pages:
Following encouraging interim data from the Phase II REDUC trial of Vacc- 4x with romidepsin, Bionor has set a number of initiatives in motion to fully capitalise on the potential opportunity that this ‘Kick and Kill’ approach could offer in HIV. This includes planning next development steps by convening an expert panel, securing future romidepsin supply and exploring potential financing options. These endeavours should ensure that Bionor will be well-placed to swiftly advance Vac